Published in N Engl J Med on June 07, 2012
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | NCT01700049
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med (2012) 4.19
Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med (2013) 2.55
Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell (2015) 2.03
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol (2015) 2.02
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr Dermatol Rep (2014) 1.79
Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell (2014) 1.74
Advanced basal cell carcinoma. Wien Med Wochenschr (2013) 1.71
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol (2012) 1.36
Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov (2013) 1.34
Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med (2015) 1.33
Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol (2012) 1.24
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20
Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med (2012) 1.19
Vismodegib. Nat Rev Drug Discov (2012) 1.16
Vismodegib. Clin Cancer Res (2012) 1.07
Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int (2014) 1.06
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet (2016) 1.05
Vismodegib (erivedge) for advanced Basal cell carcinoma. P T (2012) 1.02
Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res (2014) 1.01
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res (2013) 1.01
Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99
Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol (2014) 0.97
The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother (2013) 0.97
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci (2013) 0.96
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res (2014) 0.95
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One (2013) 0.95
The utility of hedgehog signaling pathway inhibition for cancer. Oncologist (2012) 0.94
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget (2015) 0.92
18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med (2012) 0.92
Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist (2014) 0.92
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) (2016) 0.91
Stem cell signaling as a target for novel drug discovery: recent progress in the WNT and Hedgehog pathways. Acta Pharmacol Sin (2013) 0.91
An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma. Oncoscience (2014) 0.91
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol (2014) 0.91
Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS One (2013) 0.91
Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol (2013) 0.91
CD200-expressing human basal cell carcinoma cells initiate tumor growth. Proc Natl Acad Sci U S A (2013) 0.90
Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell (2016) 0.90
Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg (2013) 0.90
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer (2014) 0.89
Canonical and non-canonical Hedgehog signalling and the control of metabolism. Semin Cell Dev Biol (2014) 0.89
Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget (2015) 0.89
Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer (2014) 0.88
Metastatic Basal cell carcinoma: a biological continuum of Basal cell carcinoma? Case Rep Dermatol Med (2012) 0.88
Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med (2015) 0.87
Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther (2014) 0.87
Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol (2013) 0.87
Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation. J Neurophysiol (2014) 0.87
Translocation affecting sonic hedgehog genes in basal-cell carcinoma. N Engl J Med (2012) 0.87
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res (2013) 0.87
Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med (2014) 0.86
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene (2013) 0.86
Novel agents for advanced pancreatic cancer. Oncotarget (2015) 0.86
Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. Med Res Arch (2016) 0.86
Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds. Cancer Med (2014) 0.85
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics (2015) 0.85
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res (2015) 0.85
Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res (2013) 0.85
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential. Mol Cancer Res (2014) 0.85
Advances in the management of basal cell carcinoma. F1000Prime Rep (2015) 0.85
Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian J Pharmacol (2014) 0.84
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis (2016) 0.84
Computational drug repositioning through heterogeneous network clustering. BMC Syst Biol (2013) 0.84
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol (2016) 0.83
Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. United European Gastroenterol J (2013) 0.83
Targeted treatment for sonic hedgehog-dependent medulloblastoma. Neuro Oncol (2014) 0.83
Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res (2014) 0.83
Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLoS One (2013) 0.83
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. Oncogene (2015) 0.83
EZH2, Proliferation Rate, and Aggressive Tumor Subtypes in Cutaneous Basal Cell Carcinoma. JAMA Oncol (2016) 0.83
Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma. J Adv Pract Oncol (2015) 0.83
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol (2013) 0.83
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist (2016) 0.82
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications. Front Surg (2016) 0.82
Neglected giant scalp Basal cell carcinoma. Plast Reconstr Surg Glob Open (2014) 0.82
Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol (2013) 0.82
Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan. Oncotarget (2016) 0.82
Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. Oncotarget (2015) 0.82
Novel therapies for the treatment of advanced prostate cancer. Curr Treat Options Oncol (2013) 0.82
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer (2017) 0.81
Sonidegib (Odomzo) for the Systemic Treatment of Adults With Recurrent, Locally Advanced Basal Cell Skin Cancer. P T (2016) 0.81
Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. Thyroid (2013) 0.81
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. Front Oncol (2016) 0.80
The hedgehog pathway in triple-negative breast cancer. Cancer Med (2016) 0.80
Medicinal history of North American Veratrum. Phytochem Rev (2014) 0.80
I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs. Nat Prod Rep (2016) 0.80
A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol (2016) 0.80
Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome. Ann Maxillofac Surg (2015) 0.79
Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome. Oncotarget (2015) 0.79
Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med (2013) 0.79
Molecular targeted agents--where we are and where we are going. Chin J Cancer (2013) 0.79
A rare case of super giant basal cell carcinoma. JAAD Case Rep (2015) 0.79
PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target. Cancer Biol Ther (2015) 0.79
Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmacol Res Perspect (2016) 0.79
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 8.55
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Sonic hedgehog signaling is essential for hair development. Curr Biol (1998) 5.58
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet (1996) 4.36
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med (2012) 4.19
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Essential role for Sonic hedgehog during hair follicle morphogenesis. Dev Biol (1999) 3.62
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol (1998) 2.00
Sonic hedgehog exerts distinct, stage-specific effects on tongue and taste papilla development. Dev Biol (2004) 1.82
Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol (2001) 1.77
Disruption of sonic hedgehog signaling alters growth and patterning of lingual taste papillae. Dev Biol (2003) 1.69
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med (2012) 4.19
Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature (2005) 4.16
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol (2008) 3.66
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res (2009) 2.77
Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A (2006) 2.72
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2013) 2.61
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol (2011) 2.58
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol (2009) 2.53
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol (2014) 2.39
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer (2009) 2.26
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.25
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res (2007) 2.25
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol (2013) 2.22
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol (2012) 2.20
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 2.12
ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park) (2011) 2.11
MIM and cortactin antagonism regulates ciliogenesis and hedgehog signaling. Dev Cell (2010) 2.11
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev (2004) 2.07
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas. Nature (2013) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res (2008) 1.99
Memory regulatory T cells reside in human skin. J Clin Invest (2014) 1.95
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res (2006) 1.86
Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov (2012) 1.86
Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst (2013) 1.80
Dual degradation signals control Gli protein stability and tumor formation. Genes Dev (2006) 1.75
Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer (2011) 1.74
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos (2003) 1.66
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Eruptive xanthomas associated with olanzapine use. Arch Dermatol (2003) 1.61
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.58
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol (2010) 1.56
Cancer of unknown primary site. Semin Oncol (2010) 1.55
Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther (2004) 1.54
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol (2014) 1.53